Kiora Pharmaceuticals Reports Its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model

Kiora Pharmaceuticals (NASDAQ: KPRX) today announced preclinical data showing that KIO-300, part of the company's novel ion channel modulator platform, significantly suppressed seizure-associated electrophysiological activity in an ex vivo temporal lobe epilepsy (TLE) model. The findings were presented in a poster at the Epilepsy Foundation Pipeline Conference taking place June 18-19, 2026, in Leesburg, VA.

Key takeaways from the data include a significant reduction in epileptiform activity, underscoring the potential of KIO-300 as a therapeutic candidate for epilepsy. KIO-300 is the active pharmaceutical ingredient of KIO-301, Kiora's ongoing Phase 2 clinical program in vision restoration for patients with gene mutation-agnostic retinitis pigmentosa. This new application of the ion channel modulator platform suggests broader therapeutic potential beyond retinal diseases.

The preclinical study utilized an ex vivo model of temporal lobe epilepsy, which is one of the most common and difficult-to-treat forms of epilepsy. The results indicate that KIO-300 can suppress abnormal electrical activity in brain tissue, providing a foundation for further development in epilepsy indications. The company plans to explore additional preclinical studies to characterize the compound's efficacy and safety profile.

Kiora Pharmaceuticals is a clinical-stage biotechnology company developing advanced therapies for retinal disease. Its pipeline includes KIO-301 for retinitis pigmentosa with potential expansion into choroideremia and Stargardt disease, and KIO-104 for macular edema due to retinal inflammation. The company targets critical pathways underlying retinal diseases using innovative small molecules to slow, stop, or restore vision loss.

In addition to news releases and SEC filings, Kiora expects to post information on its website, www.kiorapharma.com, and social media accounts that could be relevant to investors. The company encourages investors to follow them on X and LinkedIn as well as to visit their website and/or subscribe to email alerts.

Forward-looking statements in this press release relate to Kiora's ability to execute on development and commercialization efforts, the sufficiency of existing cash, timelines of anticipated readouts, and the potential for pipeline expansion. These statements involve risks and uncertainties that may cause results to differ materially, including those described under "Risk Factors" in Kiora's Annual Report on Form 10-K filed with the SEC on March 25, 2026, and other public filings.